Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

← catalyst calendar

NCT06567743 · readout in 224 d

Sponsored by CG Oncology, Inc. (industry) · CGON — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

325estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-16

actual

When the study began enrolling

Primary completion

2027-03-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-12-30

estimated

The whole study's end, after follow-up

First posted

2024-08-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

High-Risk Non-Muscle-Invasive Bladder Cancer

Intervention

Drug: Cretostimogene Grenadenorepvec — also filed as CG0070

Primary outcomes

what the primary-completion date above is the date OF

Cohort A (Arm 1 and 2): Complete response rate

measured At 11 and 24 weeks

Cohort A (Arm 3): High- Grade Event-Free Survival

measured 48 months

Cohort B (Arm 1): Complete response rate

measured At 11 and 24 weeks

Cohort B (Arm 2): High-Grade Event-Free Survival

measured 48 months

Cohort CX (Arms 1 and 2): High-Grade Event-Free Survival

measured 48 months

Cohort CX (Arms 1 and 2): Safety

measured 48 months

Permalink · CGON's whole pipeline · Catalyst calendar · Every registered study · What changed